Literature DB >> 1623478

Expression of disialogangliosides GD2 and GD3 on human soft tissue sarcomas.

H R Chang1, C Cordon-Cardo, A N Houghton, N K Cheung, M F Brennan.   

Abstract

METHODS: Fifty-six freshly frozen human sarcomas were studied for expression of disialogangliosides by avidin-biotin immunohistochemical staining with purified monoclonal antibodies (MoAb) 3F8 (antidisialoganglioside GD2) and R24 (antidisialoganglioside GD3).
RESULTS: Ninety-three percent of the tumors tested by the immunohistochemical staining expressed GD2 and 88% expressed GD3. The intensity of expression varied among sarcomas of different histologic types. Liposarcoma, fibrosarcoma, malignant fibrous histiocytoma, leiomyosarcoma, and spindle cell sarcoma reacted strongly with 3F8 and R24. Embryonal rhabdomyosarcoma and synovial sarcoma demonstrated substantially weaker staining by either MoAb. Weakly reactive or nonreactive tumors were, in general, high-grade or metastatic sarcomas. Ganglioside extraction and thin-layer chromatography/immunothin-layer chromatography of two liposarcomas confirmed the identities of these gangliosides.
CONCLUSIONS: GD2 and GD3 may indicate sites for MoAb-targeted imaging and therapy for sarcomas. The association of a diminished stainability by 3F8 and R24 with aggressive sarcomas may indicate prognostic significance.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1623478     DOI: 10.1002/1097-0142(19920801)70:3<633::aid-cncr2820700315>3.0.co;2-f

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  42 in total

1.  Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children's Oncology Group (COG) phase II study.

Authors:  Suzanne Shusterman; Wendy B London; Stephen D Gillies; Jacquelyn A Hank; Stephan D Voss; Robert C Seeger; C Patrick Reynolds; Jennifer Kimball; Mark R Albertini; Barrett Wagner; Jacek Gan; Jens Eickhoff; Kenneth B DeSantes; Susan L Cohn; Toby Hecht; Brian Gadbaw; Ralph A Reisfeld; John M Maris; Paul M Sondel
Journal:  J Clin Oncol       Date:  2010-10-04       Impact factor: 44.544

Review 2.  Anti-GD2 antibody therapy for GD2-expressing tumors.

Authors:  Fariba Navid; Victor M Santana; Raymond C Barfield
Journal:  Curr Cancer Drug Targets       Date:  2010-03       Impact factor: 3.428

Review 3.  Immunotherapeutic approaches to sarcoma.

Authors:  Melissa Burgess; Hussein Tawbi
Journal:  Curr Treat Options Oncol       Date:  2015-06

4.  Oncotargets GD2 and GD3 are highly expressed in sarcomas of children, adolescents, and young adults.

Authors:  Konstantin Dobrenkov; Irina Ostrovnaya; Jessie Gu; Irene Y Cheung; Nai-Kong V Cheung
Journal:  Pediatr Blood Cancer       Date:  2016-06-15       Impact factor: 3.167

5.  High specificity targeting and detection of human neuroblastoma using multifunctional anti-GD2 iron-oxide nanoparticles.

Authors:  Dana C Baiu; Nathan S Artz; Meghan R McElreath; Bryan D Menapace; Diego Hernando; Scott B Reeder; Cordula Grüttner; Mario Otto
Journal:  Nanomedicine (Lond)       Date:  2015-09-30       Impact factor: 5.307

6.  Severe adverse immunologic reaction in a patient with glioblastoma receiving autologous dendritic cell vaccines combined with GM-CSF and dose-intensified temozolomide.

Authors:  Duane A Mitchell; Elias J Sayour; Elizabeth Reap; Robert Schmittling; Gabriel DeLeon; Pamela Norberg; Annick Desjardins; Allan H Friedman; Henry S Friedman; Gary Archer; John H Sampson
Journal:  Cancer Immunol Res       Date:  2014-11-11       Impact factor: 11.151

7.  Phase I trial of a novel anti-GD2 monoclonal antibody, Hu14.18K322A, designed to decrease toxicity in children with refractory or recurrent neuroblastoma.

Authors:  Fariba Navid; Paul M Sondel; Raymond Barfield; Barry L Shulkin; Robert A Kaufman; Jim A Allay; Jacek Gan; Paul Hutson; Songwon Seo; Kyungmann Kim; Jacob Goldberg; Jacquelyn A Hank; Catherine A Billups; Jianrong Wu; Wayne L Furman; Lisa M McGregor; Mario Otto; Stephen D Gillies; Rupert Handgretinger; Victor M Santana
Journal:  J Clin Oncol       Date:  2014-04-07       Impact factor: 44.544

Review 8.  Targeted therapies for advanced Ewing sarcoma family of tumors.

Authors:  Yunyun Jiang; Joseph Ludwig; Filip Janku
Journal:  Cancer Treat Rev       Date:  2015-03-27       Impact factor: 12.111

9.  Peptides mimicking GD2 ganglioside elicit cellular, humoral and tumor-protective immune responses in mice.

Authors:  Assefa Wondimu; Tianqian Zhang; Thomas Kieber-Emmons; Phyllis Gimotty; Katrin Sproesser; Rajasekharan Somasundaram; Soldano Ferrone; Chun-Yen Tsao; Dorothee Herlyn
Journal:  Cancer Immunol Immunother       Date:  2008-07       Impact factor: 6.968

Review 10.  Immunity against soft-tissue sarcomas.

Authors:  Robert G Maki
Journal:  Curr Oncol Rep       Date:  2003-07       Impact factor: 5.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.